In 2013, afatinib was approved by the U.S. FDA for the first line treatment of patients with locally advanced or metastatic NSCLC who harbor nonresistant EGFR mutations.[5] The clinical effectiveness of afatinib in the treatment of such patients has been confirmed by the results of recent real-world studies.[6] Despite the high disease control rates, almost all patients eventually experience acquired resistance-mediated disease progression. Here, EGFR is linked to non-small cell lung carcinoma.